Key points are not available for this paper at this time.
There has been increasing public concern about the risks of high-dose antipsychotic (neuroleptic) treatment, arising in part from an, as yet unproven, association between high-dose treatment and death in a small minority of patients. The clinical issues related to the use of neuroleptics in doses exceeding the maximum recommended in the British National Formulary (BNF) were discussed at the Psychopharmacology Subcommittee. When, if ever, should the recommended doses be exceeded?
Hirsch et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: